Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect.

Collegium Pharmaceutical beat analysts’ revenue expectations last quarter, reporting revenues of $209.4 million, up 31.4% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Collegium Pharmaceutical’s revenue to grow 13.4% year on year, slowing from the 21.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical rarely misses Wall Street’s revenue estimates.

Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 42.6%, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported revenues up 1.4%, topping estimates by 4.8%. Eli Lilly traded up 1.7% following the results while Bristol-Myers Squibb was also up 7.6%.

Read our full analysis of Eli Lilly’s results here and Bristol-Myers Squibb’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Collegium Pharmaceutical is down 1.4% during the same time and is heading into earnings with an average analyst price target of $53.67 (compared to the current share price of $45.15).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.